Abstract
Serum albumin (SA) has been shown to be a prognostic marker in many hematological malignancies and in diffuse large B-cell lymphoma (DLBCL) prior to chemo-immunotherapy. SA may be a surrogate for age, comorbid status, and disease severity. Here, we aimed to assess whether SA can be an independent prognostic marker in patients with newly diagnosed DLBCL treated with rituximab, cyclophosphamide, vincristine, doxorubicin, and prednisone (R-CHOP). Patients who presented at the Moffitt Cancer Center from 2007 to 2010 for DLBCL diagnosis or treatment were identified using our institutional database. Clinical and treatment data were recorded, including SA levels at diagnosis. Survival time was estimated using the Kaplan-Meier method, with Cox proportional hazard model used to identify potential risk factors for time-to-event data. From 295 identified patients, 171 were excluded for not having primary treatment at our institution or not having R-CHOP treatment. In 124 included patients (mean age at diagnosis of 58 years, 91 % Caucasian), 25 % were categorized as poor by the revised International Prognostic Index. Overall and progression-free survival at 4 years were 65 % (95 % CI 57–75) and 58 % (95 % CI 0.49–0.69), respectively. Using multivariate analysis, we found that the hazard index of death of patients with SA ≥3.7 g/dL was 26 % (95 % CI 13–53) of the hazard for those patients who had SA <3.7 g/dL when controlling for the revised International Prognostic Index risk and initial lymphocyte count. Our study shows that SA ≥3.7 g/dL is an independent prognostic marker in DLBCL patients treated with R-CHOP.
Similar content being viewed by others
References
Cultrera JL, Dalia SM (2012) Diffuse large B-cell lymphoma: current strategies and future directions. Cancer Control 19(3):204–213
A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project (1993) N Engl J Med 329(14):987-994. doi:10.1056/nejm199309303291402
Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346(4):235–242. doi:10.1056/NEJMoa011795
Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, Lefort S, Marit G, Macro M, Sebban C, Belhadj K, Bordessoule D, Ferme C, Tilly H (2010) Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood 116(12):2040–2045. doi:10.1182/blood-2010-03-276246
Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, Klasa R, Savage KJ, Shenkier T, Sutherland J, Gascoyne RD, Connors JM (2007) The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 109(5):1857–1861. doi:10.1182/blood-2006-08-038257
Peyrade F, Jardin F, Thieblemont C, Thyss A, Emile JF, Castaigne S, Coiffier B, Haioun C, Bologna S, Fitoussi O, Lepeu G, Fruchart C, Bordessoule D, Blanc M, Delarue R, Janvier M, Salles B, Andre M, Fournier M, Gaulard P, Tilly H (2011) Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Oncol 12(5):460–468. doi:10.1016/s1470-2045(11)70069-9
Pavlidis AN, Kalef-Ezra J, Bourantas LC, Lambrou A, Mavridis A (1993) Serum tumor markers in non-Hodgkin’s lymphomas and chronic lymphocytic leukemia. Int J Biol Markers 8(1):14–20
Suzumiya J, Ohshima K, Kanda M, Kato A, Shuuda K, Kimura N, Tamura K, Kikuchi M (1998) Intravascular large cell lymphoma associated with hypoalbuminemia. Leuk Lymphoma 32(1–2):179–182. doi:10.3109/10428199809059259
Coiffier B, Lepage E (1993) Prognostic factors in large-cell lymphomas. Leuk Lymphoma 10(Suppl):57–60. doi:10.3109/10428199309149113
Horn H, Ziepert M, Becher C, Barth TF, Bernd HW, Feller AC, Klapper W, Hummel M, Stein H, Hansmann ML, Schmelter C, Moller P, Cogliatti S, Pfreundschuh M, Schmitz N, Trumper L, Siebert R, Loeffler M, Rosenwald A, Ott G (2013) MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood 121(12):2253–2263. doi:10.1182/blood-2012-06-435842
Visco C, Li Y, Xu-Monette ZY, Miranda RN, Green TM, Tzankov A, Wen W, Liu WM, Kahl BS, d’Amore ES, Montes-Moreno S, Dybkaer K, Chiu A, Tam W, Orazi A, Zu Y, Bhagat G, Winter JN, Wang HY, O’Neill S, Dunphy CH, Hsi ED, Zhao XF, Go RS, Choi WW, Zhou F, Czader M, Tong J, Zhao X, van Krieken JH, Huang Q, Ai W, Etzell J, Ponzoni M, Ferreri AJ, Piris MA, Moller MB, Bueso-Ramos CE, Medeiros LJ, Wu L, Young KH (2012) Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Leukemia 26(9):2103–2113. doi:10.1038/leu.2012.83
Sehn LH (2012) Paramount prognostic factors that guide therapeutic strategies in diffuse large B-cell lymphoma. Hematol Am Soc Hematol Educ Prog 2012:402–409. doi:10.1182/asheducation-2012.1.402
Perry AM, Mitrovic Z, Chan WC (2012) Biological prognostic markers in diffuse large B-cell lymphoma. Cancer Control 19(3):214–226
Ngo L, Hee SW, Lim LC, Tao M, Quek R, Yap SP, Loong EL, Sng I, Hwan-Cheong TL, Ang MK, Ngeow J, Tham CK, Tan MH, Lim ST (2008) Prognostic factors in patients with diffuse large B cell lymphoma: before and after the introduction of rituximab. Leuk Lymphoma 49(3):462–469. doi:10.1080/10428190701809156
Gupta D, Lis CG (2010) Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature. Nutr J 9:69. doi:10.1186/1475-2891-9-69
Goldwasser P, Feldman J (1997) Association of serum albumin and mortality risk. J Clin Epidemiol 50(6):693–703
Finestone HM, Greene-Finestone LS, Wilson ES, Teasell RW (1996) Prolonged length of stay and reduced functional improvement rate in malnourished stroke rehabilitation patients. Arch Phys Med Rehabil 77(4):340–345
Murray MJ, Marsh HM, Wochos DN, Moxness KE, Offord KP, Callaway CW (1988) Nutritional assessment of intensive-care unit patients. Mayo Clin Proc 63(11):1106–1115
Chihara D, Oki Y, Ine S, Yamamoto K, Kato H, Taji H, Kagami Y, Yatabe Y, Nakamura S, Morishima Y (2009) Analysis of prognostic factors in peripheral T-cell lymphoma: prognostic value of serum albumin and mediastinal lymphadenopathy. Leuk Lymphoma 50(12):1999–2004. doi:10.3109/10428190903318311
Watanabe T, Kinoshita T, Itoh K, Yoshimura K, Ogura M, Kagami Y, Yamaguchi M, Kurosawa M, Tsukasaki K, Kasai M, Tobinai K, Kaba H, Mukai K, Nakamura S, Ohshima K, Hotta T, Shimoyama M (2010) Pretreatment total serum protein is a significant prognostic factor for the outcome of patients with peripheral T/natural killer-cell lymphomas. Leuk Lymphoma 51(5):813–821. doi:10.3109/10428191003721359
Zhu YJ, Huang JJ, Xia Y, Zhao W, Jiang WQ, Lin TY, Huang HQ, Li ZM (2011) Primary mediastinal large B-cell lymphoma (PMLBCL) in Chinese patients: clinical characteristics and prognostic factors. Int J Hematol 94(2):178–184. doi:10.1007/s12185-011-0898-4
Hasenclever D, Diehl V (1998) A prognostic score for advanced Hodgkin’s disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 339(21):1506–1514. doi:10.1056/nejm199811193392104
Arcaini L, Lazzarino M, Colombo N, Burcheri S, Boveri E, Paulli M, Morra E, Gambacorta M, Cortelazzo S, Tucci A, Ungari M, Ambrosetti A, Menestrina F, Orsucci L, Novero D, Pulsoni A, Frezzato M, Gaidano G, Vallisa D, Minardi V, Tripodo C, Callea V, Baldini L, Merli F, Federico M, Franco V, Iannitto E, Integruppo Italiano L (2006) Splenic marginal zone lymphoma: a prognostic model for clinical use. Blood 107(12):4643–4649. doi:10.1182/blood-2005-11-4659
Kharfan-Dabaja MA, Chavez JC, Yu D, Zhu W, Fernandez-Vertiz EI, Perkins J, Shapiro J, Bookout R, Perez L, Fernandez HF, Komrokji RS, Lancet J, Brand L, Field T, Ayala E, Janssen W, List AF, Anasetti C (2011) Severe hypoalbuminemia at day 90 predicts worse nonrelapse mortality and overall survival after allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant 17(3):384–393. doi:10.1016/j.bbmt.2010.07.011
Komrokji RS, Corrales-Yepez M, Kharfan-Dabaja MA, Al Ali NH, Padron E, Rollison DE, Pinilla-Ibarz J, Zhang L, Epling-Burnette PK, Lancet JE, List AF (2012) Hypoalbuminemia is an independent prognostic factor for overall survival in myelodysplastic syndromes. Am J Hematol 87(11):1006–1009. doi:10.1002/ajh.23303
Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25(5):579–586. doi:10.1200/jco.2006.09.2403
Schoenfeld D (1982) Partial residuals for the proportional hazards regression model. Biometrika 69:239–241
Perry AM, Cardesa-Salzmann TM, Meyer PN, Colomo L, Smith LM, Fu K, Greiner TC, Delabie J, Gascoyne RD, Rimsza L, Jaffe ES, Ott G, Rosenwald A, Braziel RM, Tubbs R, Cook JR, Staudt LM, Connors JM, Sehn LH, Vose JM, Lopez-Guillermo A, Campo E, Chan WC, Weisenburger DD (2012) A new biologic prognostic model based on immunohistochemistry predicts survival in patients with diffuse large B-cell lymphoma. Blood 120(11):2290–2296. doi:10.1182/blood-2012-05-430389
Salles G, de Jong D, Xie W, Rosenwald A, Chhanabhai M, Gaulard P, Klapper W, Calaminici M, Sander B, Thorns C, Campo E, Molina T, Lee A, Pfreundschuh M, Horning S, Lister A, Sehn LH, Raemaekers J, Hagenbeek A, Gascoyne RD, Weller E (2011) Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium. Blood 117(26):7070–7078. doi:10.1182/blood-2011-04-345256
Mackintosh JF, Cowan RA, Jones M, Harris M, Deakin DP, Crowther D (1988) Prognostic factors in stage I and II high and intermediate grade non-Hodgkin’s lymphoma. Eur J Cancer Clin Oncol 24(10):1617–1622
Lin TL, Kuo MC, Shih LY, Dunn P, Wang PN, Wu JH, Tang TC, Chang H, Hung YS (2012) The impact of age, Charlson comorbidity index, and performance status on treatment of elderly patients with diffuse large B cell lymphoma. Ann Hematol 91(9):1383–1391. doi:10.1007/s00277-012-1463-9
Prakash G, Sharma A, Raina V, Kumar L, Sharma MC, Mohanti BK (2012) B cell non-Hodgkin’s lymphoma: experience from a tertiary care cancer center. Ann Hematol 91(10):1603–1611. doi:10.1007/s00277-012-1491-5
Steward WP, Todd ID, Harris M, Jones JM, Blackledge G, Wagstaff J, Anderson H, Wilkinson PM, Crowther D (1984) A multivariate analysis of factors affecting survival in patients with high-grade histology non-Hodgkin’s lymphoma. Eur J Cancer Clin Oncol 20(7):881–889
Khera R, Jain S, Kumar L, Thulkar S, Vijayraghwan M, Dawar R (2010) Diffuse large B-cell lymphoma: experience from a tertiary care center in North India. Med Oncol 27(2):310–318. doi:10.1007/s12032-009-9211-2
Hennig B, Honchel R, Goldblum SE, McClain CJ (1988) Tumor necrosis factor-mediated hypoalbuminemia in rabbits. J Nutr 118(12):1586–1590
Brenner DA, Buck M, Feitelberg SP, Chojkier M (1990) Tumor necrosis factor-alpha inhibits albumin gene expression in a murine model of cachexia. J Clin Invest 85(1):248–255. doi:10.1172/jci114419
McMillan DC, Watson WS, O’Gorman P, Preston T, Scott HR, McArdle CS (2001) Albumin concentrations are primarily determined by the body cell mass and the systemic inflammatory response in cancer patients with weight loss. Nutr Cancer 39(2):210–213. doi:10.1207/S15327914nc392_8
Ballmer PE, Ochsenbein AF, Schutz-Hofmann S (1994) Transcapillary escape rate of albumin positively correlates with plasma albumin concentration in acute but not in chronic inflammatory disease. Metabolism 43(6):697–705
Aviles A, Yanez J, Lopez T, Garcia EL, Guzman R, Diaz-Maqueo JC (1995) Malnutrition as an adverse prognostic factor in patients with diffuse large cell lymphoma. Arch Med Res 26(1):31–34
Acknowledgments
We thank Rasa Hamilton (Moffitt Cancer Center) for editorial assistance.
Conflict of interest
No authors have any conflicts of interest to report.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Dalia, S., Chavez, J., Little, B. et al. Serum albumin retains independent prognostic significance in diffuse large B-cell lymphoma in the post-rituximab era. Ann Hematol 93, 1305–1312 (2014). https://doi.org/10.1007/s00277-014-2031-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-014-2031-2